AlloVir, Inc. (ALVR) closed the last trading session at $7.83, gaining 45.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
Shares of AlloVir, Inc. (ALVR) have gained 24.6% over the past four weeks to close the last trading session at $5.53, but there could still be a solid upside left in the stock if short-term price ...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders.
New York, New York--(Newsfile Corp. - March 14, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 ...
ALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR WHY: ...
AlloVir (NASDAQ:ALVR) just reported results for the first quarter of 2024. AlloVir reported earnings per share of -26 cents. This was below the analyst estimate for EPS of -18 cents. The company did ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results